Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

stat rx usa llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg - kadian® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (see clinical pharmacology). kadian ® capsules are not intended for use as a prn analgesic. kadian® is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. kadian® is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines.) kadian® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule component

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

physicians total care, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 20 mg - kadian® capsules are an extended-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time (see clinical pharmacology). kadian® capsules are not intended for use as a prn analgesic. kadian® is not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild or not expected to persist for an extended period of time. kadian® is only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (see american pain society guidelines.) kadian® is contraindicated in patients with a known hypersensitivity to morphine, morphine salts or any of the capsule components, or

Israel - Englisch - Ministry of Health

novartis israel ltd - ceritinib - hard gelatin capsules - ceritinib 150 mg - ceritinib - zykadia is indicated for the treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors are anaplastic lymphoma kinase (alk)-positive.23.04.2018 בקשה לשינוי משטר מינון - dose modification for patients with severe hepatic impairment (child-pugh c), reduce the dose of zykadia by approximately one-third, rounded to the nearest multiple of the 150 mg dosage strength- new starting dose - 450 mg taken orally once daily with food (instead of 750mg taken on empty stomach).first dose reduction due to adverse reactions- 300 mg taken orally once daily with food, second dose reduction - 150 mg taken orally once daily with food. discontinue zykadia for patients unable to tolerate 150 mg daily with food.

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

bayer healthcare pharmaceuticals inc. - finerenone (unii: de2o63yv8r) (finerenone - unii:de2o63yv8r) - kerendia is indicated to reduce the risk of sustained egfr decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (ckd) associated with type 2 diabetes (t2d). kerendia is contraindicated in patients: there are no available data on kerendia use in pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. animal studies have shown developmental toxicity at exposures about 4 times those expected in humans. (see data) . the clinical significance of these findings is unclear. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%,

Israel - Englisch - Ministry of Health

bayer israel ltd - finerenon - film coated tablets - finerenon 10 mg - finerenon - kerendia is indicated to reduce the risk of sustained egfr decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (ckd) associated with type 2 diabetes (t2d).

Israel - Englisch - Ministry of Health

bayer israel ltd - finerenon - film coated tablets - finerenon 20 mg - finerenon - kerendia is indicated to reduce the risk of sustained egfr decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (ckd) associated with type 2 diabetes (t2d).

Israel - Englisch - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - magnesium chloride 0.1017 g; calcium chloride 0.1838 g; glucose as monohydrate 16.5 g; lactic acid as sodium 3.925 g; sodium chloride 5.786 g - combinations - combinations - for use in patients with end-stage (decompensated)chronic renal failure of any origin which can be treated with peritoneal dealysis.17/10/2017 בקשה לשינוי משטר מינוןשינוי משטר מינון בהתאם למאושר באירופה

Israel - Englisch - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - sodium chloride 5.786 g; lactic acid as sodium 3.925 g; glucose as monohydrate 46.75 g; calcium chloride 0.1838 g; magnesium chloride 0.1017 g - combinations - combinations - for use in patients with end-stage (decompensated )chronic renal failure of any origin which can be treated with peritoneal dealysis.17/10/2017 בקשה לשינוי משטר מינוןשינוי משטר מינון בהתאם למאושר באירופה

Israel - Englisch - Ministry of Health

fresenius medical care israel p.b. ltd - calcium chloride; glucose as monohydrate; lactic acid as sodium; magnesium chloride; sodium chloride - solution for peritoneal dialysis - magnesium chloride 0.1017 g; glucose as monohydrate 25 g; calcium chloride 0.1838 g; sodium chloride 5.786 g; lactic acid as sodium 3.925 g - combinations - combinations - for use in patients with end-stage (decompensated )chronic renal failure of any origin which can be treated with peritoneal dealysis.17/10/2017 בקשה לשינוי משטר מינוןשינוי משטר מינון בהתאם למאושר באירופה

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - glucose monohydrate, quantity: 42.5 g/l (equivalent: glucose, qty 38.6 g/l); sodium chloride, quantity: 5.38 g/l; magnesium chloride hexahydrate, quantity: 51 mg/l; calcium chloride dihydrate, quantity: 0.184 g/l; sodium bicarbonate, quantity: 2.1 g/l; sodium lactate, quantity: 1.68 g/l - solution, dialysis - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - physioneal 40 is indicated for use in peritoneal dialysis in patients with acute or chronic renal failure.